03. February 2015

Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Zedira has received further funding from the German Federal Ministry for Education and Research (German abbreviation: BMBF). The project volume has been extended by € 1.0 Mio. so that the total project value exceeds € 5.0 Mio. by now. The additional funding will allow completing the development of a drug candidate for „safe“ anticoagulation.

Zedira targets coagulation factor XIIIa (F13, plasma transglutaminase) using direct acting peptidomimetic inhibitors including proof-of-concept studies in relevant animal models. Further, Zedira continues the successful cooperation in the field of structural biology with the group of Prof. Gerhard Klebe, Marburg University.

Dr. Martin Hils, managing partner, comments: „We are more than happy to receive funding for this cutting-edge project within this highly competitive program. The grant is a special honor underlining our successful drug discovery approach over the past decade.

Dr. Ralf Pasternack, managing partner, adds: „After licensing our lead project in the field of celiac disease to Dr. Falk Pharma, the FXIII-project further strengthens our leading international position in the transglutaminase field. We are confident that our approach, due to the unique mode-of-action, will provide a safer therapeutic opportunity in anticoagulation for patients, doctors and payers.



  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation